Toleris Biotherapeutics

Toleris Biotherapeutics is an early-stage biotech developing a novel platform of AutoImmunity Modifying Biologics (AIM Bios) designed to induce targeted, antigen-specific immune tolerance for treating autoimmune diseases. Its technology is based on soluble variants of the HLA-G molecule, which naturally protects the fetus from the maternal immune system, offering a potential paradigm shift from broad immunosuppressants to precision immunomodulation. The company holds a global license for its platform across most disease areas and is actively seeking investors and partners to advance its programs. It has garnered recognition through several competitive awards and grants, positioning it as an innovative player in the autoimmune therapeutics space.

AutoImmunity Modifying Biologics (AIM Bio) platform using engineered soluble HLA-G molecules to induce antigen-specific immune tolerance, mimicking the natural tolerance mechanism of pregnancy.

The field of antigen-specific tolerance is emerging but competitive, with other biotechs exploring approaches like peptide immunotherapy, tolerogenic vaccines, and engineered regulatory T cells (Tregs). Toleris's unique angle is its direct exploitation of the HLA-G pathway, a distinct mechanism from most other players.